X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.prnewswire.com/news-releases/blueprint-medicines-reports-strong-first-quarter-2024-results-and-raises-ayvakitayvakyt-avapritinib-full-year-revenue-guidance-302133890.html
https://www.prnewswire.com/news-releases/blueprint-medicines-highlights-ayvakit-avapritinib-long-term-efficacy-and-safety-data-and-advances-in-mast-cell-disease-research-at-2024-aaaai-annual-meeting-302069445.html
https://www.fiercepharma.com/pharma/blueprint-boosts-ayvakit-peak-sales-estimate-2b-key-rare-disease-expansion-accelerates
https://www.europeanpharmaceuticalreview.com/news/190025/ec-approves-treatment-for-ism/
https://www.prnewswire.com/news-releases/blueprint-medicines-ayvakyt-avapritinib-receives-positive-chmp-opinion-as-the-first-and-only-therapy-for-indolent-systemic-mastocytosis-301984702.html
https://www.globenewswire.com/news-release/2023/08/07/2720112/8690/en/QIAGEN-receives-FDA-approval-for-companion-diagnostic-to-Blueprint-Medicines-AYVAKIT-avapritinib-in-gastrointestinal-stromal-tumors.html
https://www.prnewswire.com/news-releases/fda-approves-ayvakit-avapritinib-as-the-first-and-only-treatment-for-indolent-systemic-mastocytosis-301831282.html
https://endpts.com/ahead-of-fda-decision-blueprint-puts-out-full-data-for-expanded-ayvakit-label/
https://www.fiercepharma.com/pharma/all-eyes-blueprints-ayvakit-rare-disease-expansion-15b-sales-target
https://ir.blueprintmedicines.com/news-releases/news-release-details/blueprint-medicines-present-positive-data-pioneer-trial-ayvakitr
https://www.prnewswire.com/news-releases/blueprint-medicines-announces-fda-acceptance-of-supplemental-new-drug-application-for-ayvakit-avapritinib-for-the-treatment-of-indolent-systemic-mastocytosis-301727726.html
https://endpts.com/ash22-cogent-touts-data-on-small-subset-of-rare-disease-patients-in-bid-to-compete-with-blueprint/
https://ir.blueprintmedicines.com/news-releases/news-release-details/blueprint-medicines-submits-supplemental-new-drug-application-0
https://endpts.com/blueprint-medicines-slips-as-it-changes-endpoint-for-trial-in-aim-to-greatly-broaden-ayvakit-label/
https://www.prnewswire.com/news-releases/blueprint-medicines-ayvakyt-avapritinib-receives-european-commission-approval-for-the-treatment-of-adults-with-advanced-systemic-mastocytosis-301510840.html
https://www.prnewswire.com/news-releases/blueprint-medicines-ayvakyt-avapritinib-receives-positive-chmp-opinion-for-the-treatment-of-adults-with-advanced-systemic-mastocytosis-301470585.html
https://www.asiaone.com/business/cstone-announced-new-drug-approval-precision-therapy-ayvakit-avapritinib-hong-kong-china
https://www.prnewswire.com/news-releases/blueprint-medicines-reports-third-quarter-2021-financial-results-301410584.html
https://www.fiercepharma.com/marketing/blueprint-challenges-novartis-new-ayvakit-nod-blood-disorders-more-competition-to-follow
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-avapritinib-advanced-systemic-mastocytosis
https://www.prnewswire.com/news-releases/fda-approves-blueprint-medicines-ayvakit-avapritinib-for-the-treatment-of-adults-with-advanced-systemic-mastocytosis-301314129.html
https://en.prnasia.com/releases/apac/cstone-announces-china-nmpa-new-drug-approval-of-precision-therapy-ayvakit-avapritinib-for-the-treatment-of-adults-with-unresectable-or-metastatic-pdgfra-exon-18-mutant-gastrointestinal-stromal-tumor-313562.shtml
https://www.prnewswire.com/news-releases/blueprint-medicines-submits-supplemental-new-drug-application-to-fda-for-ayvakit-avapritinib-for-the-treatment-of-advanced-systemic-mastocytosis-301194719.html
https://www.ema.europa.eu/en/documents/overview/ayvakyt-epar-medicine-overview_en.pdf
https://www.ema.europa.eu/en/documents/overview/ayvakyt-epar-medicine-overview_en.pdf
https://seekingalpha.com/pr/18020538-blueprint-medicines-announces-european-commission-approval-of-ayvakyt-avapritinib-for
https://www.globenewswire.com/news-release/2020/09/25/2099190/0/en/Genetron-Health-and-CStone-Pharmaceuticals-Announce-Launch-of-Clinical-Trial-in-China-for-Companion-Diagnostic-Test-in-Development-for-Avapritinib.html
https://www.raps.org/news-and-articles/news-articles/2020/7/ema-thumbs-up-for-11-down-for-2-new-medicines
http://ir.blueprintmedicines.com/news-releases/news-release-details/blueprint-medicines-receives-positive-chmp-opinion-avapritinib
https://www.prnewswire.com/news-releases/blueprint-medicines-announces-publication-in-the-lancet-oncology-showing-durable-clinical-benefits-of-ayvakit-avapritinib-in-navigator-trial-patients-with-pdgfra-d842v-mutant-gist-301085276.html
http://ir.blueprintmedicines.com/news-releases/news-release-details/blueprint-medicines-presents-updated-part-1-data-pioneer-trial
https://www.fiercepharma.com/marketing/blueprint-s-ayvakit-gets-fda-no-go-new-stomach-cancer-use-but-presses-ahead-blood
https://www.prnewswire.com/news-releases/blueprint-medicines-announces-data-presentations-highlighting-significant-progress-in-advancing-ret-altered-cancer-and-systemic-mastocytosis-programs-301059013.html
http://ir.blueprintmedicines.com/news-releases/news-release-details/blueprint-medicines-announces-part-1-results-pioneer-trial
https://www.prnewswire.com/news-releases/blueprint-medicines-to-present-updated-data-from-phase-2-pioneer-trial-of-avapritinib-in-patients-with-indolent-systemic-mastocytosis-at-2020-aaaai-annual-meeting-301009943.html
https://www.prnewswire.com/news-releases/blueprint-medicines-announces-pdufa-date-extension-for-new-drug-application-of-avapritinib-for-the-treatment-of-adults-with-fourth-line-gastrointestinal-stromal-tumor-300999856.html
https://www.prnewswire.com/news-releases/pantherx-rare-pharmacy-selected-by-blueprint-medicines-corporation-to-distribute-ayvakit-avapritinib-for-genomically-defined-patient-population-with-rare-cancer-gist-300988886.html
https://www.fiercepharma.com/marketing/blueprint-wins-first-fda-nod-for-a-stomach-cancer-though-not-exactly-what-it-asked-for
https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-treat-rare-mutation-patients-gastrointestinal-stromal-tumors
https://www.prnewswire.com/news-releases/ori-biotech-announces-a-9-4m-seed-round-to-advance-innovation-in-cell-and-gene-therapy-manufacturing-300983736.html
https://www.clinicaltrialsarena.com/comment/blueprints-phase-ii-avapritinib-sparks-concerns-on-risk-benefit-profile/
https://www.prnewswire.com/news-releases/blueprint-medicines-announces-initial-data-from-phase-2-pioneer-trial-of-avapritinib-in-patients-with-indolent-systemic-mastocytosis-showing-activity-at-all-dose-levels-tested-300970999.html
https://www.prnewswire.com/news-releases/blueprint-medicines-to-present-initial-data-from-phase-2-pioneer-trial-of-avapritinib-in-patients-with-indolent-systemic-mastocytosis-at-61st-ash-annual-meeting-and-exposition-300952819.html
https://endpts.com/fda-backs-mike-greys-bet-on-a-comeback-drug-play-with-breakthrough-status-for-maralixibat/
https://www.biospectrumasia.com/news/39/14323/first-patient-dosed-for-phase-i-ii-trial-of-avapritinib-in-advanced-gist.html
https://www.biopharmadive.com/news/deciphera-gastrointestinal-cancer-drug-race-blueprint/560808/
https://www.fiercebiotech.com/biotech/deciphera-soars-as-phase-3-cancer-data-tee-up-fda-filing
https://www.prnewswire.com/news-releases/blueprint-medicines-submits-new-drug-application-to-us-food-and-drug-administration-for-avapritinib-for-the-treatment-of-pdgfra-exon-18-mutant-gist-and-fourth-line-gist-300867797.html
Market Place
Share 
